These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 6416260)

  • 21. Long-term tolerance and recovery of beta-propiolactone/ultraviolet (beta PL/UV) treated PPSB in chimpanzees.
    Stephan W; Kotitschke R; Prince AM; Brotman B
    Thromb Haemost; 1981 Aug; 46(2):511-4. PubMed ID: 7302890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative assays for evaluation of HTLV-III inactivation procedures: tri(N-butyl)phosphate:sodium cholate and beta-propiolactone.
    Prince AM; Horowitz B; Dichtelmueller H; Stephan W; Gallo RC
    Cancer Res; 1985 Sep; 45(9 Suppl):4592s-4594s. PubMed ID: 2410108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of beta-propiolactone on some routine haematological tests.
    Atrah HI; Allardyce M; Davidson RJ
    Med Lab Sci; 1988 Oct; 45(4):308-11. PubMed ID: 3268715
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of beta-propiolactone on routine biochemical investigations.
    Dooley BJ; Harling NP; Lloyd G; van Heyningen C
    Med Lab Sci; 1985 Oct; 42(4):318-21. PubMed ID: 4079681
    [No Abstract]   [Full Text] [Related]  

  • 25. Effect of beta-propiolactone--an inhibitor of HTLV III/LAV activity--on immunological analyses.
    Ball MJ; Spriggs V; Sutton PM; Chapel H
    J Immunol Methods; 1986 Dec; 95(1):113-6. PubMed ID: 3640791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation of virus inactivation and removal for the manufacturing procedure of two immunoglobulins and a 5% serum protein solution treated with beta-propiolactone.
    Dichtelmüller H; Rudnick D; Breuer B; Gänshirt KH
    Biologicals; 1993 Sep; 21(3):259-68. PubMed ID: 8117439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [On the problem of the use of beta-propiolactone in the sterilization of some labile biological preparations. (Preliminary communication)].
    GEFEN NE; RUDNEVA OA; BAZHINOV AG
    Zh Mikrobiol Epidemiol Immunobiol; 1962 Mar; 33():103-8. PubMed ID: 13897488
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical evaluation of the hepatitis safety of a beta-propiolactone/ultraviolet treated factor IX concentrate (PPSB).
    Heinrich D; Kotitschke R; Berthold H
    Thromb Res; 1982 Oct; 28(1):75-83. PubMed ID: 7157232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Inactivation of phages by beta-propiolactone].
    HAGIWARA S
    Sapporo Igaku Zasshi; 1962 Jul; 20():16-8. PubMed ID: 13903649
    [No Abstract]   [Full Text] [Related]  

  • 30. Sterilization of regenerated collagen sutures with beta-propiolactone.
    BALL EL; DORNBUSH AC; SIEGER GM; STIRN FE; VITUCCI JC; WEIDENHEIMER JF
    Appl Microbiol; 1961 Jul; 9(4):269-72. PubMed ID: 13686364
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inactivation of retroviruses by beta-propiolactone.
    Lancet; 1985 Jan; 1(8419):56. PubMed ID: 2856986
    [No Abstract]   [Full Text] [Related]  

  • 32. Multicenter crossover comparison of the safety and efficacy of Intraglobin-F with Gamimune-N, Sandoglobulin, and Gammagard in patients with primary immunodeficiency diseases.
    Schiff RI; Williams LW; Nelson RP; Buckley RH; Burks W; Good RA
    J Clin Immunol; 1997 Jan; 17(1):21-8. PubMed ID: 9049782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The safety of beta-propiolactone as a biologic sterilizing agent. Clinical evaluation with human plasma and homotransplants.
    LOGRIPPO GA
    Angiology; 1961 Feb; 12():80-3. PubMed ID: 13763188
    [No Abstract]   [Full Text] [Related]  

  • 34. Sterilization of instruments and materials with beta-propiolactone.
    ALLEN HF; MURPHY JT
    J Am Med Assoc; 1960 Apr; 172():1759-63. PubMed ID: 13792743
    [No Abstract]   [Full Text] [Related]  

  • 35. Identification of target antigens of self-reactive IgG in intravenous immunoglobulin preparations.
    Bussone G; Dib H; Dimitrov JD; Camoin L; Broussard C; Tamas N; Guillevin L; Kaveri SV; Mouthon L
    Proteomics; 2009 Apr; 9(8):2253-62. PubMed ID: 19296548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Various immunoglobulin preparations for intravenous use.
    Morell A
    Vox Sang; 1986; 51 Suppl 2():44-9. PubMed ID: 2945321
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Monitoring of sterilization procedures for plasma derivatives using bacteriophages].
    Dichtelmüller H; Stephan W
    Immun Infekt; 1988 Feb; 16(1):18-20. PubMed ID: 3283031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of combined treatment of serum containing hepatitis B virus with beta-propiolactone and ultraviolet irradiation.
    Stephan W; Berthold H; Prince AM
    Vox Sang; 1981 Sep; 41(3):134-8. PubMed ID: 7331286
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Potency studies of sample rabies vaccine, inactivated by beta-propiolactone].
    Akan E
    Turk Hij Tecr Biyol Derg (1961); 1976; 36(2):172-88. PubMed ID: 1023462
    [No Abstract]   [Full Text] [Related]  

  • 40. [The reaction of beta-propiolactone with serum proteins and amino acid derivatives (author's transl)].
    Determann H; Joachim HU
    Z Klin Chem Klin Biochem; 1971 Sep; 9(5):398-401. PubMed ID: 5173516
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.